Helpline
0800 121 8721
Email us
Fundraising Donate

Nivolumab-ipilimumab combination shows promise for kidney cancer brain metastases

Nivolumab-ipilimumab combination shows promise for kidney cancer brain metastases

21 Jun 2019

Tags
brain metastases ipilimumab nivolumab Opdivo renal cell carcinoma Yervoy
Listen to this News
Print this News

Share this Page:

FacebookXLinkedInWhatsAppTumblrPinterestVkXingEmail

An interim analysis of study Checkmate 920 has shown that patients with advanced renal cell carcinoma (RCC) and brain metastases may benefit from treatment with the ipilimumab/nivolumab combination therapy. The results from this interim analysis were presented at the 2019 American Society of Clinical Oncology (ASCO) in Chicago earlier this month.

Read more in Cancer Therapy Advisor here

Listen to this News
Print this News

Share this Page:

FacebookXLinkedInWhatsAppTumblrPinterestVkXingEmail

Kidney cancer news

30 Apr 2025

UK regulators approve injectable form of nivolumab for solid tumours

Read More

28 Apr 2025

Immunotherapy for the treatment of non-clear cell kidney cancer

Read More

7 Apr 2025

IKCC Global Kidney Cancer Summit

Read More

2 Apr 2025

Europe has approved subcutaneous nivolumab for solid tumours

Read More

28 Mar 2025

The Big Cancer52 Conversation

Read More

24 Mar 2025

A urine test to detect the return of kidney cancer

Read More

24 Mar 2025

Spotting symptoms early: the importance of early diagnosis

Read More

24 Mar 2025

Health-related quality of life with belzutifan versus everolimus for advanced kidney cancer

Read More

10 Mar 2025

Combinations of pembrolizumab and targeted therapies for advanced clear cell kidney cancer

Read More

10 Mar 2025

Safe Sick Pay Campaign Update

Read More

27 Feb 2025

FDA grants Priority Review status for TLX250-CDx for kidney cancer PET/CT scans

Read More

25 Feb 2025

Kidney cancer research highlights from ASCO GU 2025

Read More

Most used tags

renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib cabozantinib Sutent progression-free survival kidney cancer NHS England biomarkers ipilimumab pembrolizumab Cabometyx COVID-19 axitinib cancer survival non-clear cell kidney cancer VEGF inhibitors Inlyta coronavirus Yervoy risk factors adjuvant therapy Keytruda metastases targeted therapy everolimus papillary RCC biological markers ASCO Afinitor cancer outcomes first-line treatment NICE

Archives

Address

Action Kidney Cancer

11th Floor
3 Piccadilly Place
Manchester M1 3BN

Helpline

0800 121 8721
Email Us

About Action Kidney Cancer

We are the UK’s largest and most active patient-led kidney cancer charity. Whether you are a patient, survivor or someone you know has been diagnosed with kidney cancer, you have come to the right place to find support and information, and to be part of a caring and knowledgeable community of people: We are here to help you.
Registered charity in England, Wales (1164238), and Scotland (SC051330).
© Copyright Action Kidney Cancer 2021

Links

Home

About us

Donate

Contact us

Our partners

Branding by Kingswood Marketing

Policies

Website Policies

Complaints Policy

Equal Opportunities Policy

Information Governance Policy

Social Media Policy

Health Information Policy

Follow

X-Twitter
Our Website Design Specialist | Douglass Digital

Helpline: 0800 121 8721

support@actionkidneycancer.org

Go to Top